Amoy Diagnostics
39 Dingshan Road
Xiamen
Fujian
361027
China
Tel: +86-592-6892985
Fax: +86-592-6806839
Website: http://www.amoydiagnostics.com/
16 articles about Amoy Diagnostics
-
Alercell® to Distribute AmoyDx® Ros1 Gene Fusion Detection Kit
8/8/2022
Alercell ® announced today that it has started the distribution of AmoyDx ROS1 Gene Fusion Detection Kit. Part of the master distribution agreement with Amoy Diagnostics Co., Ltd (AmoyDx), signed last month.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
8/17/2021
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. announced that the Ministry of Health, Labour and Welfare has approved the AmoyDx® Pan Lung Cancer PCR Panel as a companion diagnostic for TEPMETKO® a Merck KGaA, Darmstadt, Germany product that received approval by the Japanese MHLW in March 2020.
-
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
6/30/2021
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. announced that the AmoyDx® Pan Lung Cancer PCR Panel, an in vitro diagnostic reagent developed as a companion diagnostic for multiple anti-cancer agents, was approved by Ministry of Health, Labour and Welfare for production and marketing in Japan on June 25, 2021.
-
AmoyDx Lung Cancer PCR Panel accepted into LC-SCRUM as Screening Test for Pharma Clinical Trials in Japan
9/30/2019
Amoy Diagnostics Co., Ltd (AmoyDx, SZSE:300685), a leading company in companion diagnostics for precision oncology, today announced that the AmoyDx Lung Cancer PCR Panel has been accepted as first-line screening for patients who will potentially benefit from targeted therapy in the Lung Cancer Genomic Screening Project for Individualized Medicine (LC-SCRUM) in Japan.
-
AmoyDx and PREMIA Jointly Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network
6/24/2019
AmoyDx and PREMIA will provide large-scale cancer patient screening in Asia to support LOXO-292 RET inhibitor clinical development leveraging AmoyDx’s proprietary multi-gene polymerase chain reaction (PCR) and next generation sequencing (NGS) panels to identify patients with this rare genetic alteration.
-
AmoyDx's Plasmid Diagnostic for EGFR Mutations Approved in China
1/26/2018
Last year, AmoyDx's EGFR diagnostic was approved for use in the EU.
-
China FDA Grants Liquid Biopsy Approval to AmoyDx Super-ARMS EGFR Mutation Test
1/22/2018
Amoy Diagnostics announced that CFDA approved its Super-ARMS EGFR Mutation Test for use with plasma samples, as a companion diagnostic for NSCLC therapy with EGFR-TKIs on January 19.
-
Amoy Diagnostics Co. LTD. Starts IPO On Shenzhen Stock Exchange
8/8/2017
-
Amoy Diagnostics Co. LTD. ROS1 Diagnostics Test Contributed To A Phase 2 Clinical Study Of Crizotinib In Lung Cancer
6/15/2016
-
Amoy Diagnostics Co. LTD. Got CFDA Approval For Its ROS1 And ALK&ROS1 Testing Kits
9/3/2014
-
Amoy Diagnostics Co. LTD. to Supply ROS1 Diagnostic Kits for Pivotal Clinical Trial of Crizotinib in Asia
8/29/2013
-
SFDA Approval for Amoy Diagnostics Co. LTD.'s EML4-ALK Test
3/22/2013
-
CE Marking for Amoy Diagnostics Co. LTD.'s EML4-ALK Test
1/2/2013
-
New Lung Cancer Mutation Panel from Amoy Diagnostics Co. LTD.
9/20/2011
-
Amoy Diagnostics Co. LTD. and AstraZeneca PLC Co-host Physician Workshop
9/9/2011